A Phase 3 interventional study of Ruxolitinib (RUX) and Best Available Therapy (BAT) in Corticosteroid Refractory Acute Graft vs Host Disease, sponsored by Novartis Pharmaceuticals. Completed at 103 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 3, and was the 2nd registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Bambino Gesù Hospital and Research Institute · Sites in Austria, Czechia, Denmark and 6 more countries
Ages 3 mo–25 yrs
Novartis Pharmaceuticals · Sites in China
Ages 12–100
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 4 · Phase 4 3
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 54 across the 27 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Graft vs Host Disease by Novartis: 2 open now, 4 under way, none of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 12 studies in Graft vs Host Disease by Novartis, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 3, and was the 6th registered.
Novartis’s Graft vs Host Disease studies by the year they started, since 2012.
6 of the studies testing ruxolitinib in Graft vs Host Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07238712St. Petersburg State Pavlov Medical UniversityOptimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | 2026-12-10 |
| NCT06936566John LevineMAGIC Ruxolitinib for aGVHD | 2027-06-01 |
| NCT06008808Washington University School of MedicineRuxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | 2027-09-08 |
| NCT07796620Peking University People's HospitalSirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | 2027-09-30 |
| NCT07356245Ohio State University Comprehensive Cancer CenterRuxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 27 studies testing ruxolitinib in Graft vs Host Disease, from their registry updates:
Among Novartis’s 12 in Graft vs Host Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic stem cell transplantation.
This randomized, phase III, open-label study investigated the efficacy and safety of ruxolitinib vs. BAT added to the patient's immunosuppressive regimen in adults and adolescents (≥ 12 years old) with grade II-IV Steroid-refractory Acute Graft vs. Host Disease (SR-aGvHD). During the screening period, patients were monitored for a diagnosis of SR-aGvHD, which was defined as patients who had high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with CNI, who either:
Failed corticosteroid taper defined as fulfilling either one of the following criteria:
Patients meeting eligibility criteria were randomized 1:1 to receive either ruxolitinib or BAT stratifying on aGvHD grade at the time of randomization (Grade II vs III vs IV).
Study treatment began on Day 1 (no later than 72 hours after randomization) followed by regular visits for assessments of efficacy and safety. Study treatment was administered until the patient met any of the criteria for discontinuation of study treatment or, in responders (i.e. patients achieving PR or CR) until the dosing schedule for ruxolitinib or BAT was completed.
All responders were to be tapered off during the treatment period by, first tapering from corticosteroids, followed by CNI and ruxolitinib. A slow tapering extending beyond 24 weeks was permitted for ruxolitinib at Investigator's discretion rather than an abrupt cessation, as the latter could result in an aGvHD flare.
During the Treatment Period, patients randomized to BAT could have crossed over to ruxolitinib between Day 28 and Week 24 if they:
AND
Patients who crossed over to ruxolitinib were followed until completion of treatment with ruxolitinib and received the same treatment and tapering schedule as patients randomized to ruxolitinib treatment.
The End of Treatment (EOT) visit occurred when the patient completed the study treatment period or earlier if the patient met any of the criteria for discontinuation of study treatment.
Patient's treatment period was up to 6 months (Week 24). However, ruxolitinib taper could be delayed up to 2 years from randomization due to an aGvHD flare or other safety concerns.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of aGvHD defined as patients administered high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with calcineurin inhibitors (CNI) and either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These patients were administered Ruxolitinib orally twice per day (b.i.d) at a dose of 10 mg bid, as two 5-mg tablets. Ruxolitinib was taken without regards to food.
Drug: Ruxolitinib (RUX)
These patients were administered BAT per the Investigator's best judgement based on a specific list of BAT.
Drug: Best Available Therapy (BAT)
Ruxolitinib was provided as 5 mg tablets for oral use.
Also known as: INC424
BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Overall Response Rate (ORR) at Day 28
Overall response rate at Day 28 after randomization was defined as the percentage participants in each arm demonstrating a complete response (CR) or partial response (PR), based on investigator assessment \& according to standard criteria, without requirement for additional systemic therapies for an earlier progression, mixed response or non-response. Scoring of response was relative to the organ stage at the time of randomization. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs \& symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Time frame: Day 28
Durable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 56
Percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Time frame: Day 56
Overall Response Rate (ORR) at Day 14
ORR at Da4 14 is the percentage of participants who achieved overall response (CR+PR) at Day 14 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Time frame: Day 14
Duration of Response (DOR)
Duration of response was defined for patients who had a CR or PR at Day 28. This was the interval between the date of first documented response of CR or PR (i.e., the start date of response), till the date of progression or addition of systemic therapies for aGvHD on or after Day 28. Death without prior observation of aGvHD progression and onset of chronic GvHD were considered. Duration of response was censored at the last response assessment prior to or at the analysis cut-off date, if no events/competing risk occurred before or at the cut-off date.
Time frame: Up to 24 months
Cumulative Steroid Dosing Until Day 56
Weekly cumulative steroid dose for each participant up to Day 56 or discontinuation of randomized treatment. Participants should have undergone tapering of steroids if it had been required. Tapering the immunosuppression therapy was performed in 2 steps: Taper of corticosteroids: initiated not earlier than Day 7, and performed as per institutional guidelines. Only patients with assessments done at each time point are reported. This is the reason that the overall number per treatment is higher and the number of participants with responses vary over time.
Time frame: up to Day 56
Kaplan Meier Estimates of Probability of Overall Survival (OS) by Time Interval
OS was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.
Time frame: 1, 2, 6, 12, 18 & 24 months
Kaplan Meier Estimates of Probability of Event-free Survival (EFS) by Time Interval
Event-free survival was defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. If a patient was not known to have any event, then EFS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.
Time frame: 1, 2, 6, 12, 18 & 24 months
Cumulative Incidence Rate of Failure-Free Survival (FFS)
FFS was defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. Probability of FFS with 95% CIs are presented for each treatment group, accounting for onset of chronic GvHD as the competing risk.
Time frame: 1, 2, 6, 12, 18, & 24 Months
Cumulative Probability of Non Relapse Mortality (NRM)
NRM was defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression. Hematologic disease relapse/progression was considered a competing risk for NRM with the date of hematologic disease relapse/progression being the earlier of documented hematologic disease relapse/progression or institution of therapy to treat potential hematologic disease relapse/progression. If a patient was not known to have died or to have relapsed/progressed, then NRM was censored at the latest date the patient was known to be alive (on or before the cut-off date). Data is provided based on cumulative probability of hematologic disease relapse/progression.
Time frame: 1, 2, 6, 12, 18 & 24 months
Cumulative Probability of Malignancy Relapse/Progression (MR)
MR was defined as the time from date of randomization to hematologic malignancy relapse/progression. Deaths not preceded by hematologic malignancy relapse/progression were considered competing risks. If a patient was not known to have event or competing risks, then MR was censored at the latest date the patient was known to be alive (on or before the cut-off date). Calculated for patients with underlying hematologic malignant disease.
Time frame: 1, 2, 6, 12 , 18 & 24 months
Cumulative Probability of Chronic Graft Versus Host Disease (cGvHD)
Incidence of cGvHD was the time from date of randomization to onset of cGvHD is the diagnosis of any cGvHD including mild, moderate, severe. Deaths without prior onset of cGvHD and hematologic disease relapse/progression were competing risks. If a patient was not known to have event or competing risks, then the incidence of cGvHD was censored at the latest date the patient was known to be alive (on or before the cut-off date).
Time frame: 1, 2, 6, 12, 18 & 24 months
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. ORR was defined as the percentage of participants with a best overall response defined as complete response (CR) or partial response (PR) as assessed by local investigators. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Time frame: Day 28
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR)
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. DORR is the percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Time frame: Day 56
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. This represents the percentage of Ruxolitinib-exposed participants dead at 24 months. Overall survival (OS) was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date).the date of death due to any cause.
Time frame: up to 24 months
Best Overall Response Rate (BOR)
Percentage of participants who achieved overall response (OR) (CR+PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Time frame: up to Day 28
Patient Reported Outcomes (PROs): Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Total Score
The Functional assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family and emotional well-being, together with additional concerns relevant for bone marrow transplantation patients. Patients indicated their response on a scale of 0 to 4 on each statement, with 0 indicating worst score and 4 the best score. All individual scores were combined to calculate the total score. Total score was reported with score range: 0-148 which was calculated as the sum of all unweighted subscale scores. The higher the total score the better the result. Descriptive statistics and change from baseline were calculated in total score at each scheduled assessment time point.
Time frame: Baseline, Week 24
Patient Reported Outcomes (PROs): Change From Baseline in EuroQol-5D-5L UK Score
The EQ-5D descriptive classification consists of five dimensions of health: mobility, self-care, usual activities, anxiety/depression and pain/discomfort. Patients are requested to select the statement which best describes their condition on that day for each dimension. For overall health that day, the EuroQoL-5D-5L scale is numbered from 0 to 100, with 100 being the best health you can imagine and 0 being the worst health you can imagine. Descriptive statistics (mean, standard deviation, median, Q1, Q3, minimum, and maximum) were calculated based on the scored scales at each scheduled assessment time point. In order to measure Quality-of-Life (QoL) among aGvHD patients, and potential changes over time, change from baseline in EuroQol-5D-5L scores at the time of each assessment were also calculated. Missing items data in a scale will be handled based on each instrument manual. No imputation will be applied if the total or subscale scores are missing at a visit.
Time frame: Baseline, Week 24
Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC) (AUCinf, AUClast, AUCtau) of Ruxolitinib
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) AUCinf: The AUC from time zero to infinity (mass x time x volume-1) AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: Plasma Concentration at Peak (Cmax) of Ruxolitinib
Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass X volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: CL/F of Ruxolitinib
CL/F is the total body clearance of ruxolitinib from the plasma after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for Ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: VzF of Ruxolitinib
VzF is the apparent volume of distribution during terminal phase after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: Lambda_z of Ruxolitinib
Lambda_z is the smallest (slowest) disposition (hybrid) rate constant (hr-1) may also be used for terminal elimination rate constant (hr-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: T1/2 of Ruxolitinib
T1/2 is the elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: Tmax of Ruxolitinib
Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose and repeated dose administration (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: Racc of Ruxolitinib
Racc is the accumulation ratio (AUC at steady state/AUC Day 1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Time frame: pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Pharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib
Minimum concentration (Ctrough) of ruxolitinib and at steady state in corticosteroid refractory acute GVHD patients. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS)
Time frame: pre-dose
A total of 310 patients with SR-aGvHD were enrolled, out of which 309 patients were included in the analysis (as one patient did not sign the study informed consent prior to receiving BAT (protocol deviation) and was excluded from all analyses). Completed = Completed the treatment period Not completed = Discontinued from treatment period
| Milestone | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Started | 154 | 155 |
| Not treated | 2 | 5 |
| Crossover treatment at end of randomized treatment | 0 | 49 |
| Entered long-term follow-up | 102 | 51 |
| Completed screening & randomized | 154 | 155 |
| Completed screening & not randomized | 0 | 1 |
| Completed | 35 | 20 |
| Not completed | 119 | 135 |
| Withdrew: Technical problems | 0 | 1 |
| Withdrew: Lack of efficacy | 32 | 69 |
| Withdrew: Adverse event | 27 | 5 |
| Withdrew: Death | 25 | 22 |
| Withdrew: Failure to meet protocol continuation criteria | 13 | 10 |
| Withdrew: Disease relapse | 8 | 13 |
| Withdrew: Physician decision | 8 | 9 |
| Withdrew: Subject/guardian decision | 4 | 6 |
| Withdrew: Graft loss | 2 | 0 |
Overall response rate at Day 28 after randomization was defined as the percentage participants in each arm demonstrating a complete response (CR) or partial response (PR), based on investigator assessment \& according to standard criteria, without requirement for additional systemic therapies for an earlier progression, mixed response or non-response. Scoring of response was relative to the organ stage at the time of randomization. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs \& symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
| Percentage of participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Overall Response Rate (ORR) at Day 28 | 62.3 (54.2 to 70.0) | 39.4 (31.6 to 47.5) |
Percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
| Percentage of participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Durable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 56 | 39.6 (31.8 to 47.8) | 21.9 (15.7 to 29.3) |
ORR at Da4 14 is the percentage of participants who achieved overall response (CR+PR) at Day 14 based on investigator assessment and according to standard criteria. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
| Percentage of participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Overall Response Rate (ORR) at Day 14 | 63.0 (54.8 to 70.6) | 47.1 (39.0 to 55.3) |
Duration of response was defined for patients who had a CR or PR at Day 28. This was the interval between the date of first documented response of CR or PR (i.e., the start date of response), till the date of progression or addition of systemic therapies for aGvHD on or after Day 28. Death without prior observation of aGvHD progression and onset of chronic GvHD were considered. Duration of response was censored at the last response assessment prior to or at the analysis cut-off date, if no events/competing risk occurred before or at the cut-off date.
| Days | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Duration of Response (DOR) | 167.0 (22.0 to 677.0) | 106.0 (10.0 to 526.0) |
Weekly cumulative steroid dose for each participant up to Day 56 or discontinuation of randomized treatment. Participants should have undergone tapering of steroids if it had been required. Tapering the immunosuppression therapy was performed in 2 steps: Taper of corticosteroids: initiated not earlier than Day 7, and performed as per institutional guidelines. Only patients with assessments done at each time point are reported. This is the reason that the overall number per treatment is higher and the number of participants with responses vary over time.
| mg | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| By Week 1 | 962.5 (140.0 to 2337.5) | 923.6 (140.0 to 6093.8) |
| By Week 2 | 1740.0 (280.0 to 3500.0) | 1725.0 (280.0 to 7173.3) |
| By Week 3 | 2375.0 (350.0 to 5250.0) | 2340.0 (370.0 to 8000.0) |
| By Week 4 | 2866.9 (420.0 to 7000.0) | 2816.3 (420.0 to 9050.0) |
| By Week 5 | 3268.1 (455.0 to 8750.0) | 3290.6 (420.0 to 9825.0) |
| By Week 6 | 3606.3 (490.0 to 10500.0) | 3543.8 (420.0 to 10435.0) |
| By Week 7 | 3850.0 (495.0 to 11250.0) | 3706.3 (420.0 to 10955.0) |
| By Week 8 | 4000.0 (857.5 to 9475.0) | 4006.3 (420.0 to 11875.0) |
OS was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.
| Percentage of participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| 1 Month | 90.04 (84.02 to 93.87) | 85.48 (78.79 to 90.19) |
| 2 Months | 77.95 (70.42 to 83.79) | 75.69 (67.92 to 81.83) |
| 6 Months | 58.38 (50.03 to 65.82) | 49.42 (40.89 to 57.37) |
| 12 Months | 49.27 (40.96 to 57.05) | 42.71 (34.39 to 50.75) |
| 18 Months | 42.94 (34.82 to 50.79) | 37.97 (29.86 to 46.03) |
| 24 Months | 38.65 (30.50 to 46.72) | 35.55 (27.57 to 43.59) |
Event-free survival was defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. If a patient was not known to have any event, then EFS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.
| Percentage of participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| 1 Month | 89.38 (83.24 to 93.35) | 82.83 (75.81 to 87.97) |
| 2 Months | 74.60 (66.82 to 80.82) | 71.72 (63.71 to 78.26) |
| 6 Months | 53.68 (45.34 to 61.30) | 44.14 (35.82 to 52.13) |
| 12 Months | 44.53 (36.36 to 52.36) | 39.98 (30.90 to 46.96) |
| 18 Months | 40.29 (32.30 to 48.12) | 35.09 (27.23 to 43.04) |
| 24 Months | 34.98 (27.01 to 43.04) | 32.38 (24.61 to 40.37) |
FFS was defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. Probability of FFS with 95% CIs are presented for each treatment group, accounting for onset of chronic GvHD as the competing risk.
| Cumulative probability of FFS | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| 1 Month | 17.92 (12.26 to 24.46) | 49.13 (40.94 to 56.80) |
| 2 Months | 35.39 (27.79 to 43.07) | 61.32 (53.00 to 68.61) |
| 6 Months | 53.67 (45.28 to 61.34) | 80.17 (72.52 to 85.89) |
| 12 Months | 58.64 (50.18 to 66.16) | 80.91 (73.32 to 86.54) |
| 18 Months | 59.35 (50.88 to 66.84) | 80.91 (73.32 to 86.54) |
| 24 Months | 61.48 (53.01 to 68.88) | 81.66 (74.12 to 87.19) |
NRM was defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression. Hematologic disease relapse/progression was considered a competing risk for NRM with the date of hematologic disease relapse/progression being the earlier of documented hematologic disease relapse/progression or institution of therapy to treat potential hematologic disease relapse/progression. If a patient was not known to have died or to have relapsed/progressed, then NRM was censored at the latest date the patient was known to be alive (on or before the cut-off date). Data is provided based on cumulative probability of hematologic disease relapse/progression.
| Cumulative probability of NRM | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| 1 Month | 9.96 (5.83 to 15.39) | 14.52 (9.45 to 20.64) |
| 2 Months | 20.71 (14.61 to 27.54) | 23.54 (17.04 to 30.65) |
| 6 Months | 37.59 (29.81 to 45.33) | 42.42 (34.18 to 50.41) |
| 12 Months | 43.91 (35.75 to 51.77) | 46.11 (37.68 to 54.12) |
| 18 Months | 46.03 (37.77 to 53.89) | 49.21 (40.63 to 57.22) |
| 24 Months | 49.53 (40.91 to 57.55) | 49.99 (41.38 to 57.99) |
MR was defined as the time from date of randomization to hematologic malignancy relapse/progression. Deaths not preceded by hematologic malignancy relapse/progression were considered competing risks. If a patient was not known to have event or competing risks, then MR was censored at the latest date the patient was known to be alive (on or before the cut-off date). Calculated for patients with underlying hematologic malignant disease.
| Cumulative probability of MR | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| 1 Month | 0.69 (0.06 to 3.51) | 2.80 (0.92 to 6.54) |
| 2 Months | 4.21 (1.73 to 8.46) | 4.29 (1.75 to 8.60) |
| 6 Months | 8.46 (4.60 to 13.79) | 13.49 (8.32 to 19.91) |
| 12 Months | 10.68 (6.24 to 16.47) | 15.06 (9.56 to 21.71) |
| 18 Months | 12.91 (7.96 to 19.09) | 16.72 (10.89 to 23.64) |
| 24 Months | 14.75 (9.32 to 21.37) | 18.81 (12.46 to 26.17) |
Incidence of cGvHD was the time from date of randomization to onset of cGvHD is the diagnosis of any cGvHD including mild, moderate, severe. Deaths without prior onset of cGvHD and hematologic disease relapse/progression were competing risks. If a patient was not known to have event or competing risks, then the incidence of cGvHD was censored at the latest date the patient was known to be alive (on or before the cut-off date).
| Cumulative probability of cGvHD | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| 1 Month | 0 (NA to NA) | 1.33 (0.26 to 4.34) |
| 2 Months | 1.34 (0.26 to 4.39) | 2.03 (0.55 to 5.41) |
| 6 Months | 15.60 (10.26 to 21.96) | 12.19 (7.40 to 18.25) |
| 12 Months | 29.66 (22.41 to 37.25) | 20.24 (13.98 to 27.34) |
| 18 Months | 32.48 (24.96 to 40.20) | 23.36 (16.62 to 30.76) |
| 24 Months | 36.00 (28.20 to 43.84) | 24.95 (18.00 to 32.50) |
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. ORR was defined as the percentage of participants with a best overall response defined as complete response (CR) or partial response (PR) as assessed by local investigators. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
| Percentage of participants | Ruxolitinib (RUX) |
|---|---|
| Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate | 82.2 |
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. DORR is the percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56. CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
| Percentage of participants | Ruxolitinib (RUX) |
|---|---|
| Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR) | 91.0 |
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. This represents the percentage of Ruxolitinib-exposed participants dead at 24 months. Overall survival (OS) was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date).the date of death due to any cause.
| Percentage of participants | Ruxolitinib (RUX) |
|---|---|
| Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival | 53.3 |
Percentage of participants who achieved overall response (OR) (CR+PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD. PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
| Percentage of participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Best Overall Response Rate (BOR) | 81.8 (74.8 to 87.6) | 60.6 (52.5 to 68.4) |
The Functional assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family and emotional well-being, together with additional concerns relevant for bone marrow transplantation patients. Patients indicated their response on a scale of 0 to 4 on each statement, with 0 indicating worst score and 4 the best score. All individual scores were combined to calculate the total score. Total score was reported with score range: 0-148 which was calculated as the sum of all unweighted subscale scores. The higher the total score the better the result. Descriptive statistics and change from baseline were calculated in total score at each scheduled assessment time point.
| scores on a scale | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Baseline | 89.00 (41.0 to 138.0) | 81.00 (29.0 to 129.0) |
| Week (W) 24 | 108.50 (67.0 to 139.0) | 86.00 (21.0 to 124.0) |
| Change from Baseline to W24 | 9.00 (-40.0 to 44.0) | 4.50 (-29.0 to 41.0) |
The EQ-5D descriptive classification consists of five dimensions of health: mobility, self-care, usual activities, anxiety/depression and pain/discomfort. Patients are requested to select the statement which best describes their condition on that day for each dimension. For overall health that day, the EuroQoL-5D-5L scale is numbered from 0 to 100, with 100 being the best health you can imagine and 0 being the worst health you can imagine. Descriptive statistics (mean, standard deviation, median, Q1, Q3, minimum, and maximum) were calculated based on the scored scales at each scheduled assessment time point. In order to measure Quality-of-Life (QoL) among aGvHD patients, and potential changes over time, change from baseline in EuroQol-5D-5L scores at the time of each assessment were also calculated. Missing items data in a scale will be handled based on each instrument manual. No imputation will be applied if the total or subscale scores are missing at a visit.
| scores on a scale | Ruxolitinib (RUX) | Best Available Therapy (BAT) |
|---|---|---|
| Baseline | 0.60 (-0.6 to 1.0) | 0.54 (-0.6 to 1.0) |
| W24 | 0.78 (0.4 to 1.0) | 0.68 (-0.1 to 1.0) |
| Change from Baseline to W24 | 0.12 (-0.3 to 1.1) | 0.12 (-0.2 to 0.3) |
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) AUCinf: The AUC from time zero to infinity (mass x time x volume-1) AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| ng*hr/mL | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 AUCinf | 529.6 ± 55.2 |
| Week 1 Day 1 AUClast | 522.9 ± 89.6 |
| Week 1 Day 1 AUCtau | 578.9 ± 97.5 |
| Week 1 Day 7 AUCinf | 440.9 ± 91.5 |
| Week 1 Day 7 AUClast | 597.3 ± 73.2 |
| Week 1 Day 7 AUCtau | 651.9 ± 86.4 |
Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass X volume-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| ng/mL | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 | 118 ± 70.4 |
| Week 1 Day 7 | 129.3 ± 76.0 |
CL/F is the total body clearance of ruxolitinib from the plasma after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was assayed for Ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| L/hr | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 CL/F | 18.88 ± 55.2 |
| Week 1 Day 7 CL/F | 23.31 ± 89.4 |
VzF is the apparent volume of distribution during terminal phase after a single dose and at steady state. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| Liters (L) | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 | 52.57 ± 46.4 |
| Week 1 Day 7 | 66.76 ± 71.6 |
Lambda_z is the smallest (slowest) disposition (hybrid) rate constant (hr-1) may also be used for terminal elimination rate constant (hr-1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| 1/hr | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 | 0.3592 ± 34.2 |
| Week 1 Day 7 | 0.3492 ± 31.0 |
T1/2 is the elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| hour (hr) | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 | 1.93 ± 34.2 |
| Week 1 Day 7 | 1.985 ± 31.0 |
Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose and repeated dose administration (hr). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| hour (hr) | Ruxolitinib (RUX) |
|---|---|
| Week 1 Day 1 | 1.767 (0.5167 to 8.917) |
| Week 1 Day 7 | 1.542 (0.5 to 4.083) |
Racc is the accumulation ratio (AUC at steady state/AUC Day 1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients was be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
| ratio | Ruxolitinib (RUX) |
|---|---|
| Pharmacokinetic (PK) Parameter: Racc of Ruxolitinib | 1.145 ± 27.2 |
Minimum concentration (Ctrough) of ruxolitinib and at steady state in corticosteroid refractory acute GVHD patients. Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis. The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS)
| ng/ml | Ruxolitinib (RUX) |
|---|---|
| Pharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib | 17.22 ± 187.1 |
On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 708 days (treatment duration ranged from 6.0 to 678.0) for the RUX arm and 218 days (treatment duration ranged from 1.0 to 188.0 days) for the BAT arm. Deaths post treatment survival follow up were collected after the on- treatment period, up to approx. 48 months. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored.
| Participants | Ruxolitinib (RUX) | Best Available Therapy (BAT) | Cross-Over |
|---|---|---|---|
| Total Deaths | 89 | 89 | 29 |
| Deaths on-treatment | 43 | 36 | 19 |
Collected over On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 708 days (treatment duration ranged from 6.0 to 678.0) for the RUX arm and 218 days (treatment duration ranged from 1.0 to 188.0 days) for the BAT arm. Deaths occurred from Randomization till end of the study, up to approx. 48 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib (Rux) | 89/152 (58.6%) | 101/152 (66.4%) | 144/152 (94.7%) |
| Best Available Therapy (BAT) | 89/150 (59.3%) | 80/150 (53.3%) | 136/150 (90.7%) |
| Cross-Over | 29/49 (59.2%) | 38/49 (77.6%) | 43/49 (87.8%) |
| Event | Ruxolitinib (Rux) | Best Available Therapy (BAT) | Cross-Over |
|---|---|---|---|
| SepsisInfections and infestations | 12/152 | 10/150 | 7/49 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 6/152 | 6/150 | 6/49 |
| PyrexiaGeneral disorders | 10/152 | 6/150 | 0/49 |
| Septic shockInfections and infestations | 10/152 | 8/150 | 3/49 |
| PneumoniaInfections and infestations | 7/152 | 8/150 | 2/49 |
| DiarrhoeaGastrointestinal disorders | 8/152 | 3/150 | 0/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/152 | 0/150 | 2/49 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/152 | 1/150 | 2/49 |
| IleusGastrointestinal disorders | 1/152 | 1/150 | 2/49 |
| Cytomegalovirus infection reactivationInfections and infestations | 3/152 | 6/150 | 2/49 |
| Event | Ruxolitinib (Rux) | Best Available Therapy (BAT) | Cross-Over |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 61/152 | 47/150 | 16/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 56/152 | 30/150 | 14/49 |
| Cytomegalovirus infection reactivationInfections and infestations | 38/152 | 30/150 | 8/49 |
| Oedema peripheralGeneral disorders | 37/152 | 32/150 | 5/49 |
| NeutropeniaBlood and lymphatic system disorders | 36/152 | 19/150 | 10/49 |
| HypokalaemiaMetabolism and nutrition disorders | 34/152 | 28/150 | 10/49 |
| Platelet count decreasedInvestigations | 31/152 | 24/150 | 6/49 |
| NauseaGastrointestinal disorders | 30/152 | 16/150 | 3/49 |
| PyrexiaGeneral disorders | 29/152 | 21/150 | 9/49 |
| VomitingGastrointestinal disorders | 25/152 | 16/150 | 5/49 |
Full Analysis Set (FAS): The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization.
| Age, Continuous(years) | Ruxolitinib (RUX) | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Mean | 48.1 ± 16.30 | 50.9 ± 14.97 | 49.5 ± 15.69 |
| Age, Customized(Participants) | Ruxolitinib (RUX) | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Adolescents, 12 - <18 years | 5 | 4 | 9 |
| 18 - 65 years | 128 | 126 | 254 |
| >65 years | 21 | 25 | 46 |
| Sex: Female, Male(Participants) | Ruxolitinib (RUX) | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Female | 62 | 64 | 126 |
| Male | 92 | 91 | 183 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib (RUX) | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| White | 111 | 102 | 213 |
| Black or African American | 0 | 1 | 1 |
| Asian | 19 | 29 | 48 |
| Other | 8 | 4 | 12 |
| Unknown | 16 | 19 | 35 |
| Weight(kg) | Ruxolitinib (RUX) | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Mean | 67.5 ± 14.04 | 66.2 ± 14.78 | 66.9 ± 14.41 |
Showing the first 100 of 103 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Mar 2017 to primary completion in Jun 2019, 27 months.
Results were first posted in Feb 2023, 3 years 7 months after primary completion.
Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib